Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

The inhibition of histone deacetylase (HDAC) can induce differentiation, growth arrest, and apoptosis in cancer cells. This phase II multicenter study was undertaken to estimate the efficacy of belinostat, a potent inhibitor of both class I and class II HDAC enzymes, for the treatment of myelodyspla...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Cashen, Amanda, Juckett, Mark, Jumonville, Alcee, Litzow, Mark, Flynn, P. J., Eckardt, John, LaPlant, Betsy, Laumann, Kristina, Erlichman, Charles, DiPersio, John
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3557843/
https://ncbi.nlm.nih.gov/pubmed/21538061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-011-1240-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky